Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.

Kissling E., Rose A., Emborg H-D., Gherasim A., Pebody R., Pozo F., Trebbien R., Mazagatos C., Whitaker H., Valenciano M., European IVE group .

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

DOI

10.2807/1560-7917.ES.2019.24.1900121

Type

Journal article

Publication Date

2019-02-01T00:00:00+00:00

Volume

24

Keywords

Europe, influenza, multicentre study, test-negative design, vaccination, vaccine effectiveness, vaccines and immunisation, Adolescent, Adult, Aged, Case-Control Studies, Child, Europe, Female, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Outcome Assessment, Health Care, Population Surveillance, Primary Health Care, Reverse Transcriptase Polymerase Chain Reaction, Seasons, Sensitivity and Specificity, Vaccination, Vaccine Potency

Permalink More information Close